 |
| Anno II | Numero 10 | Febbraio 2017 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases |
| Programmed death ligand 1 (PD-L1) expression determined by immunohistochemistry (IHC) may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies; however, little is known about intertumoral heterogeneity of PD-L1 expression determined by IHC in lung adenocarcinomas (ADCs), and there have been conflicting results on the prognostic role of PD-L1 expression in ADCs. PD-L1 expression was evaluated in resected stage II and III ADCs by using various cutoffs and correlated with … |
| Continua a leggere |
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors |
| The contribution of programmed cell death ligand-1 (PD-L1) immune checkpoint molecule toward progression of non-small cell lung cancer (NSCLC) has not yet been elucidated, in part, because of lack of a standardised method to evaluate PD-L1 expression. In this study, we developed a novel method for the evaluation of PD-L1 expression on NSCLC cells and examined its correlation with clinicopathological characteristics. After immunohistochemical examination of PD-L1 expression for surgically … |
| Continua a leggere |
Real-world data on nivolumab treatment of non-small cell lung cancer |
| Checkpoint inhibitors have proven effectiveness in clinical trials for non-small cell lung cancer (NSCLC) patients, but if this is congruent with routine patient care is discussed. We present real-world experience with the PD1-inhibitor nivolumab in NSCLC. Patients with NSCLC were considered eligible for nivolumab treatment after one or more lines of chemotherapy, and when in reasonable performance status (PS) [Eastern Cooperative Oncology Group (ECOG) < 3]. Treatment was given … |
| Continua a leggere |
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer |
| Because most lung cancers are diagnosed at advanced stages, we are forced to conduct molecular testing using small biopsy samples. Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is emerging as a minimally invasive biopsy technique. Here, we examined the usefulness of EBUS-TBNA to evaluate programmed death-ligand 1 (PD-L1) expression in lung cancer. Using 97 consecutive cases of lung cancer diagnosed by EBUS-TBNA, from which 20 transbronchial biopsy … |
| Continua a leggere |
A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer |
| Nonsmall cell lung cancer (NSCLC)-patients treated with standard chemotherapy experienced progression rapidly. A novel therapy based on programed death 1 (PD-1)/programed death ligand 1 (PD-L1) inhibitors showed an increasing potential in several malignancies including advanced NSCLC. This article is a meta-analysis aiming to systematically evaluate the efficacy and safety profiles of PD-1/PD-L1 agents in patients with NSCLC. Data were collected from eligible studies searched … |
| Continua a leggere |
| Appuntamenti AIOM |
pd-L1: Un riferimento emergente nell’immuno-oncologia |
| Sassari, 20 febbraio 2017 Bari, 18 marzo 2017 Napoli, 23 marzo 2017 Aci Castello (CT), 25 marzo 2017 Parma, 12 aprile 2017 |
| Innovazione e sostenibilità |
| Roma, 21 febbraio 2017 |
| Cancer Immunotherapy in a Real Life Context |
| Chieti, 3 marzo 2017 |
| Studi Clinici: Metodologia A good foundation |
| Negrar (VR), 8 – 9 marzo 2017 |
| Debating the way to lung cancer The international and Italian viewpoint |
| Milano, 9 marzo 2017 |
| cROSs tALK Percorsi e prospettive nella gestione del NSCLC ALK+ e ROS1 |
| Roma, 14 – 15 marzo 2017 |
| Pink Lung Cancer 3 Diagnosi e terapia nel NSCLC: discutere con esperti in rosa |
| Bari, 23 marzo 2017 |
| Studi Clinici: Criticità Interpretative Confidence, directness, relevance |
| Negrar (VR), 24 – 25 marzo 2017 |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| Approccio multidisciplinare nel trattamento del microcitoma polmonare: tra tradizione e prospettive future |
| Roma, 31 marzo 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo incondizionato di  |